

**Table SVI. Baseline and follow-up data on obese patients with moderate to severe psoriasis who underwent bariatric surgery and patients with matching body mass index (BMI) ( $\pm 2$  units) and moderate to severe psoriasis who did not have surgery**

	Surgery group (matched BMI)						Control group (matched BMI)					
	Baseline	<i>n</i>	Follow-up > 0 but $\leq 1$ years	<i>n</i>	Follow-up $\geq 1$ but $\leq 2$ years	<i>n</i>	Baseline	<i>n</i>	Follow-up > 0 but $\leq 1$ years	<i>n</i>	Follow-up $\geq 1$ but $\leq 2$ years	<i>n</i>
BMI, kg/m <sup>2</sup> , median (IQR)	34.4 (32.0–36.4)	15	26.5 (25.0–33.7)	11	26.0 (25.8–29.1)	5	34.6 (32.8–38.0)	17	34.6 (31.8–38.2)	15	35.0 (32.8–41.0)	11
Weight, kg, median (IQR)	100.0 (95.0–112.0)	15	82.0 (73.0–100.0)	11	80.0 (76.0–84.0)	5	98.6 (96.0–101.0)	17	100.0 (96.7–108.0)	15	98.0 (91.0–105.0)	11
PASI, median (IQR)	2.7 (1.2–7.3)	14	6.0 (2.4–8.4)	11	3.8 (1.2–6.4)	5	4.8 (1.5–8.5)	17	2.4 (0.4–6.0)	13	2.2 (1.2–4.6)	10
DLQI, median (IQR)	1.0 (0.0–14.0)	15	4.0 (2.0–18.0)	9	2.0 (1.0–6.0)	4	6.0 (2.0–9.0)	17	3.0 (1.0–13.0)	15	2.0 (0.0–8.0)	11
Pso treatment, <i>n</i> (%)		15		15		15		17		17		17
No treatment	3 (20.0)		5 (33.3)		11 (73.3)		1 (5.9)		2 (11.8)		6 (35.3)	
Non-biologic systemic	5 (33.3)		7 (46.7)		3 (20.0)		10 (58.8)		10 (58.8)		4 (23.5)	
Biologic systemic	7 (46.7)		3 (20.0)		1 (6.7)		6 (35.3)		5 (29.4)		7 (41.2)	
PsoA, <i>n</i> (%)		15		11		5		17		15		11
Ongoing	7 (46.7)		4 (36.4)		1 (20.0)		3 (17.6)		3 (20.0)		1 (9.1)	
Previous	1 (6.7)		1 (9.1)		1 (20.0)		0 (0)		1 (6.7)		1 (9.1)	
No	6 (40.0)		4 (36.4)		2 (40.0)		6 (35.3)		5 (33.3)		4 (36.4)	
Unknown	1 (6.7)		2 (18.2)		1 (20.0)		8 (47.1)		6 (40.0)		5 (45.5)	

IQR: interquartile range; DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area Severity Index; Pso: psoriasis; PsoA: psoriatic arthritis. *n* denotes 100% of participants in each category.